Drug Landscape ›
liquid lactulose ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 9
Most-reported reactions
Cardiac Failure Congestive — 1 report (11.11%) Fall — 1 report (11.11%) Hip Fracture — 1 report (11.11%) Hypoaesthesia — 1 report (11.11%) Intestinal Mass — 1 report (11.11%) Non-Hodgkin^S Lymphoma — 1 report (11.11%) Off Label Use — 1 report (11.11%) Urinary Tract Infection — 1 report (11.11%) Weight Decreased — 1 report (11.11%)
Source database →
liquid lactulose in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is liquid lactulose approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for liquid lactulose in United States?
Cumberland Pharmaceuticals is the originator. The local marketing authorisation holder may differ — check the official source linked above.